Cancer colique en occlusion : quelle prise en charge en 2022 ? [Obstructed colon cancer: which strategy in 2022?]
Fiche du document
15 juin 2022
- doi: 10.53738/REVMED.2022.18.786.1192
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.786.1192
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35703861
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4C3D99FB86148
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
A. Girardot-Miglierina et al., « Cancer colique en occlusion : quelle prise en charge en 2022 ? [Obstructed colon cancer: which strategy in 2022?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.786.1192
Métriques
Partage / Export
Résumé
The key priority for obstructed colon cancer (OCC) is urgent resolution of the large bowel obstruction with ideally no compromise of oncological outcomes and low initial and permanent ostomy rates. Proactive management is pivotal to decrease the risk of perforation and septic shock. Staged procedures have an important place to provide optimal treatment and offer similar treatment and outcomes as in the elective setting. The approach is tailored to the patient's condition, the oncological situation and expertise of the available surgical team. This overview concludes by proposing a comprehensive treatment algorithm for individualized treatment of OCC.